SPG, CVS stock sentiment
☕ Morning. We tracked where the market spent its attention this past day. It clustered around these few names.
How to read each name below: first line = how morningowl sentiment moved since yesterday, second = where it stands now (-100 to +100).
Owns, develops, and manages shopping malls and mixed-use retail properties in North America, Asia, and Europe.
Each group's sentiment and how much it drove today's overall move:
News sentiment -96; led today's move.
Analyst sentiment -54; added to it.
Both groups are focused on the same concern: redemption risk tied to the SPG.PR.J preferred shares, whose price appreciation potential is characterized as exhausted. News commentary framed the preferred cautiously even while acknowledging that Simon Property Group's underlying financials remain robust. Analyst commentary echoed that same caution, pointing to the same redemption-risk thesis rather than the common stock. The two groups align closely, both distinguishing a dim view of the preferred issue from the company's otherwise solid financial footing.
As of 2026-09-25, Simon Property Group carried a P/E of 14.3, with its last close near the bottom of its trailing three-month range at the 12.7 percentile yet higher within its 12-month range at the 72.6 percentile, and down 4.6% over the past month. Over the last 90 days, open-market insider transactions showed 28 purchases and 0 sales, a net purchase of about $533,051 (excludes option exercises and awards). As of 2026-09-01, analyst opinion across 26 analysts leaned between 10 favorable and 16 neutral, with none cautious. It is scheduled to report earnings on 2026-11-02.
Operates health insurance plans, pharmacy benefit management, and retail pharmacy services across the United States.
Each group's sentiment and how much it drove today's overall move:
Retail sentiment +92; led today's move.
News sentiment -9.
Retail commentary rallied around fundamentals, citing the 4.8% rebound to $89.13 after eight losing sessions, Q2 revenue of $106.1B and raised full-year 2026 adjusted EPS guidance of $7.90-$8.10, alongside the dividend, moat, and an imminent Medicare star rating catalyst. News commentary focused narrowly on the $20.5 million settlement with Criteo over website tracking that allegedly shared protected health information without consent. The groups diverge sharply: retail leaned favorable on earnings and technicals reclaiming the 200-day EMA, while news stayed cautious around the privacy litigation.
As of 2026-09-25, CVS Health carried a P/E of 23.3, with its last close at the 9.5 percentile of its trailing 3-month range and 64.3 of its 12-month range, after a decline of 5.5% over the past month. As of 2026-09-01, coverage leans favorable, with 28 favorable and 5 neutral opinions across 33 analysts and none cautious. As of 2026-09-27, it is scheduled to report earnings on 2026-10-27.
That's all two of them tucked in for the night, same time tomorrow, same owl. 🦉☕
This is not investment advice. morningowl is a publisher, not a registered investment adviser. We may hold positions in any security mentioned. Past performance and historical commentary patterns do not predict future results. Our data and analysis are provided "as is" and may contain inaccuracies; we accept no liability for errors or for any decisions made in reliance on them.
Important: please read
morningowl publishes information, not financial advice. Nothing we publish is a recommendation, solicitation, or offer to buy or sell any security, and nothing here should be taken as investment, legal, tax, or accounting advice. We are not a registered investment adviser, broker-dealer, or financial planner, and no content constitutes a fiduciary relationship of any kind. Our notes describe aggregated public commentary and may be incomplete, delayed, or wrong. Markets carry risk, including loss of principal. Always do your own research and consult a licensed professional before making any financial decision. You are solely responsible for your own decisions.